- Adoption of digital breast tomosynthesis (DBT; also known as 3D mammography) into clinical practice has been rapid, jumping from 12.9% to 43.2% of mammography screenings during a recent 3-year period.
Why this matters
- DBT appears to have a lower recall rate and higher cancer detection rate, which is offset by higher cost and higher radiation dose with some machines.
- Longitudinal analysis of nearly 9.7 million screening claims in a US private health insurance database (Blue Cross Blue Shield or BCBS) from January 1, 2015, to December 31, 2017.
- To assess the generalizability of the findings, BCBS claims for DBT were compared with those of Medicare fee-for-service, according to hospital referral region (HRR).
- Funding: NIH; American Cancer Society.
- DBT use rose from 12.9% to 43.2% of screening claims during the 3-year study period.
- DBT as the predominant mode of screening (i.e., used in >50% of mammography screenings) grew from 4.6% of HRRs to 41.8% of HRRs during the same period.
- HRR-level use of DBT in the BCBS population was strongly correlated with that in the Medicare population (r, 0.85 in 2015 [P<.001 r in>
- Most rapid growth was in the Northeast and Northwest United States.
- Reliance on claims data.